At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 196 enrolled
Drug / intervention
Placebo +2 moredrug
Likely dose
Placebo 980 milligramfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Omega-3 Fatty Acids for Treatment of Major Depression: Differential Effects of EPA and DHA, and Associated Biochemical and Immune Parameters
In Brief
A Phase 3 clinical trial evaluating eicosapentaenoic acid, docosahexaenoic acid, and 1 other intervention for Major Depressive Disorder. Completed, enrolled 196 participants across 1 site.
Detailed Summary
This study examines the difference in the effectiveness of two natural compounds, eicosapentanoic (EPA) and docosahexanoic (DHA)omega-3 fatty acids, in treating major depressive disorder. Both types of omega-3 fatty acids are commonly found in fish oils. It is believed that a deficiency in these omega-3 fatty acids may lead to the development of major depression.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMajor Depressive Disorder
CountriesUnited States
Timeline
Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJul 2006
First PostedAug 2006
Primary CompletionFeb 2013
Study CompletionMar 2013
TodayJul 2026
First PostedAug 8, 2006
Enrollment StartJul 1, 2006
Primary CompletionFeb 1, 2013
Study CompletionMar 1, 2013
TodayJul 2, 2026
Enrollment to primary: 6.6 yearsPosted 19.9 years ago
Interventions
eicosapentaenoic aciddietary
1 gram/day
docosahexaenoic aciddietary
1 gram/day
Placebodrug
980 milligram/day